Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving ...

Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for ...

Thermo Fisher Scientific TMO recently announced a collaboration with Pfizer to increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients. The ...

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.

Dublin, Sept. 09, 2019 (GLOBE NEWSWIRE) -- The "Global NGS-Based Monitoring and Diagnostic Test Market: Focus on Application, Method, Type, End User, Country Data (17 Countries), and Competitive ...